Atrial Fibrillation Market To 2022: Top Industry Players, Revenue By 2026

Atrial fibrillation is becoming common among individuals due to the various factors such as hypertension, high alcohol intake, rising number of people with common diseases such as diabetes and obesity. However, with the growth in atrial fibrillation, the procedures and devices providing diagnoses and treatment are also increasing. Technologically advanced procedures are being adopted by the hospitals and clinics to treat atrial fibrillation. Meanwhile, favorable regulatory steps by the government in various countries is also leading to the rise in adoption of advanced procedures for diagnoses and treatment of atrial fibrillation.

Request a sample of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1541

The emergence of new technologies is leading towards high-resolution image and mapping system that can be used to identify complexity across the entire atrial chamber. Similarly, a combination of laser and video technology is also resulting in the high success rate in the treatment of atrial fibrillation. Increasing use of less invasive treatments is resulting in the manufacturers coming up with the new devices for diagnoses and treatment of atrial fibrillation. Catheter ablation is a minimally invasive therapy gaining popularity across the countries. With the quick adoption of catheter ablation, manufacturers are also coming up with new devices that are smart and able to provide treatment in an effective and safer way. Key market players have already launched advanced atrial fibrillation devices in Europe, and are now preparing to launch those devices in the U.S. based on the adoption in Europe.

However, the high cost of treatment and lack of skilled professionals are restricting the growth of atrial fibrillation market. Although, the government in various countries are introducing various programs and regulations to provide treatment for a maximum number of people suffering from atrial fibrillation.  

EP Ablation Catheters Likely to be the Top-Selling Product in the Global Atrial Fibrillation Market

EP ablation catheters are likely to be one of the top-selling products in the global atrial fibrillation market during 2017-2026. By the end of 2026, EP ablation catheters are projected to reach nearly US$ 2,700 million revenue. Meanwhile, EP mapping and recording systems are also likely to witness significant growth during 2017-2026.

Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1541

Hospital are Likely to Gain Maximum Revenue Share

Hospitals are anticipated to be the largest end-users in the global atrial fibrillation market between 2017 and 2026. Hospitals are projected to surpass US$ 4,400 million revenue by the end of 2026. Although electrophysiology labs are also likely to witness impressive growth during 2017-2026.

EP Ablation to Witness Significant Growth in the Global Atrial Fibrillation Market

EP ablation is likely to account for nearly one-third of the revenue share by the end of 2017. Towards the end of 2026, EP ablation is projected to bring in more than US$ 5,000 million revenue.

Europe to Remain Dominant in the Global Atrial Fibrillation Market between 2017 and 2026

Europe is likely to dominate the global market for atrial fibrillation through 2026. Owing to the rise in the adoption of technologically advanced technologies and advanced healthcare facilities and infrastructure is driving the growth in Europe. Most of the devices often get approval in Europe before entering the U.S. market, hence the region is set to witness robust growth during 2017-2026. Moreover, increasing number of catheter ablation procedures performed in Germany is also contributing to the market growth.

Competition Tracking

The report also offers a detailed profile of various leading companies that are expected to remain active in the expansion of global atrial fibrillation market through 2026, which include Medtronic Plc, Abbott Laboratories, MicroPort Scientific Corporation, Biosense Webster, Inc., Biotronik SE & Co. KG, Boston Scientific Corporation, CardioFocus, Inc., Osypka AG, AtriCure Inc., and Koninklijke Philips N.V.  

Enquiry for discount on this report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1541

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com

This release was published on openPR.